FY26 Update
| Stock | Compumedics Ltd (CMP.ASX) |
|---|---|
| Release Time | 6 Jul 2026, 10:43 a.m. |
| Price Sensitive | Yes |
Compumedics Ltd FY26 Update
- Record FY26 shipped and invoiced revenue of $60.3M, up 18% year-on-year
- Somfit and Nexus 360 SaaS recurring revenue up 70% YoY
- FY26 EBITDA expected to grow, supported by revenue and cost discipline
Compumedics Ltd reported a record FY26 shipped and invoiced revenue of approximately $60.3 million, up 18% year-on-year. The company also reported FY26 sales orders of approximately $62.7 million, reflecting continued demand across its sleep, neurology, MEG, and connected platform businesses. Somfit and Nexus 360 SaaS recurring revenues increased approximately 70% on FY25. FY26 EBITDA is anticipated to grow, supported by revenue growth, cost discipline, and increasing contribution from higher quality recurring revenue platforms. The company expects to deliver further double-digit revenue growth in FY27, with EBITDA growth at a faster rate than revenue.
FY26 shipped and invoiced revenue approximately $60.3M, FY26 EBITDA growth expected
Compumedics targets double-digit revenue growth in FY27, driven by order book conversion, MEG activity, and the planned release of Somfit D in the USA.